South San Francisco Commercial Real Estate Broker

South San Francisco is the most concentrated biotech CRE submarket in the U.S.

South San Francisco is the original biotech cluster — home to one of the original Bay Area biotech anchor tenants and a dense ecosystem of biotech tenants, contract research organizations, and lab REITs. The submarket combines lab REIT anchor demand with proximity to SFO, BART access, and the Highway 101 / Interstate 280 corridor. Lab and R&D rents here are among the highest in the United States. Multifamily development is concentrated along the El Camino corridor and around BART stations.

For institutional CRE owners, this means South San Francisco is the place where biotech-specialized capital (Alexandria, BioMed, Healthpeak, IQHQ) competes directly for lab and R&D product, often at compressed cap rates relative to broader Bay Area institutional product.

Career South San Francisco track record

• Icon at Airport · 480 unitsTOD development sale adjacent to BART · pricing record at close

Current South San Francisco market intelligence

Lab / R&D. Class A lab product clearing 4.75–5.25% cap rates on stabilized assets with credit tenant. Major life science REITs active. Spec-built lab continues to come online; demand absorbing it on biotech tenant rebound.

Multifamily. TOD product near South San Francisco BART clearing 4.40–4.85% cap rates. El Camino corridor product clearing 4.65–5.10%.

Office. Biotech-adjacent office clearing on lab-conversion thesis. Class B with conversion potential bid by lab-specialty value-add capital.

Development. El Camino Real / Mission Road and Oyster Point precise plans continue to unlock biotech and mixed-use development. Density-bonus opportunities priced aggressively.

Related practice areas active in South San Francisco